Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. 2013

Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
Research and Development Department, Novagli Pharma SAS, Evry Cedex, France.

OBJECTIVE The aim of this study was to compare the ocular and systemic distribution of cyclosporine A (CsA) in rabbits after the instillation of preservative-free CsA cationic and anionic emulsions. METHODS For the single-dose pharmacokinetic (PK) study, rabbits were instilled with 50 μL of the test material. For the multiple-dose PK study, rabbits were instilled twice daily with Restasis or once daily with NOVA22007 for 10 days. At each time point, the cornea, conjunctiva, and whole blood were harvested for CsA quantification. Ocular and systemic distribution were determined after 4 times daily instillations with 50 μL of 3H-CsA cationic and anionic emulsions for 7 days. Restasis was used as a reference in all studies. RESULTS Single-dose PK data demonstrated that NOVA22007 0.1% and 0.05% delivered higher CsA concentrations to the cornea than Restasis [concentration maximum (C max): 2692, 1372, and 748 ng/g, respectively] and have a better exposition (area under the curve). Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively. The multiple-dose PK and the 3H-CsA distribution data demonstrated that the systemic distribution after repeated instillations was low and comparable for all emulsions. CONCLUSIONS These data demonstrate that the CsA cationic emulsions were more effective than Restasis at delivering CsA to target tissues, thus confirming the potential advantage of cationic emulsions over anionic emulsions as vehicle for ocular drug delivery for the treatment of ocular surface diseases.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D011310 Preservatives, Pharmaceutical Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants. Pharmaceutic Aids (Preservatives),Pharmaceutic Preservative,Pharmaceutic Preservatives,Pharmaceutical Preservative,Pharmaceutical Preservatives,Preservative, Pharmaceutic,Preservative, Pharmaceutical,Preservatives, Pharmaceutic
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003228 Conjunctiva The mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball. Bulbar Conjunctiva,Palpebral Conjunctiva,Plica Semilunaris of Conjunctiva,Plicae Semilunares of Conjunctiva,Tunica Conjunctiva,Conjunctiva, Bulbar,Conjunctiva, Palpebral,Conjunctivas
D003315 Cornea The transparent anterior portion of the fibrous coat of the eye consisting of five layers: stratified squamous CORNEAL EPITHELIUM; BOWMAN MEMBRANE; CORNEAL STROMA; DESCEMET MEMBRANE; and mesenchymal CORNEAL ENDOTHELIUM. It serves as the first refracting medium of the eye. It is structurally continuous with the SCLERA, avascular, receiving its nourishment by permeation through spaces between the lamellae, and is innervated by the ophthalmic division of the TRIGEMINAL NERVE via the ciliary nerves and those of the surrounding conjunctiva which together form plexuses. (Cline et al., Dictionary of Visual Science, 4th ed) Corneas
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier

Related Publications

Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
February 1999, Current eye research,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
February 2017, European journal of drug metabolism and pharmacokinetics,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
April 1990, Research communications in chemical pathology and pharmacology,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
May 2004, Lipids,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
January 1994, Life sciences,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
October 2010, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
January 1991, European journal of drug metabolism and pharmacokinetics,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
December 1994, Acta ophthalmologica,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
March 1965, Meditsinskaia radiologiia,
Philippe Daull, and Frédéric Lallemand, and Betty Philips, and Grégory Lambert, and Ronald Buggage, and Jean-Sébastien Garrigue
June 2004, Chemotherapy,
Copied contents to your clipboard!